Caldwell Sutter Capital, Inc. Pacira Bio Sciences, Inc. Transaction History
Caldwell Sutter Capital, Inc.
- $234 Billion
- Q3 2025
A detailed history of Caldwell Sutter Capital, Inc. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Caldwell Sutter Capital, Inc. holds 149 shares of PCRX stock, worth $3,343. This represents 0.0% of its overall portfolio holdings.
Number of Shares
149Holding current value
$3,343% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PCRX
# of Institutions
260Shares Held
51.1MCall Options Held
289KPut Options Held
130K-
Black Rock Inc. New York, NY8.01MShares$180 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.41MShares$121 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.4MShares$53.8 Million0.08% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.25MShares$50.6 Million0.04% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.15MShares$48.3 Million0.01% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.03B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...